Articles From This Issue
Optimizing MIGS Outcomes
By Chelvin Sng, MBBChir, MA, FRCS(Ed), and Jing Wang, MD, FRCSC
Microinvasive glaucoma surgery (MIGS) has carved out a niche in the glaucoma treatment algorithm, fulfilling a previously unmet need for safer glaucoma surgery that can…
New Directions for GT
Supplements and CME
CyPass Micro-Stent
Sponsored by Alcon
Iqbal “Ike” K. Ahmed, MD, FRCSC, moderator; John Davidson, MD; Sean Ianchulev, MD, MPH; Richard Lewis, MD; Karolinne Maia Rocha, MD, PHD; Farrell "Toby" Tyson, MD
XEN45: The Next Generation of MIGS
Sponsored by Allergan Global Medical Affairs
Robert N. Weinreb, MD, moderator; Iqbal “Ike” K. Ahmed, MD, FRCSC; John Berdahl, MD; Davinder S. Grover, MD, MPH; Steven R. Sarkisian Jr, MD; Inder Paul Singh, MD; and Steven D. Vold, MD
CME - 1 Credit
Current and Emerging Glaucoma Therapy
By THOMAS SAMUELSON, MD, MODERATOR; JASON BACHARACH, MD; MURRAY FINGERET, OD; L. JAY KATZ, MD
NEWS
EyeGate Pharma Submits Investigational Device Exemption Amendment for Second Pil…
EyeGate Pharmaceuticals announced that it has submitted an amended Investigational Device Exemption …
Icon Bioscience Receives FDA Approval for Dexycu Drug Therapy for Treating Infla…
Icon Bioscience announced that the FDA has approved the company's new drug application for Dexyc…
EyeGate Announces Topline Results for Phase 2b Trial of EGP-437 in Cataract Surg…
EyeGate Pharmaceuticals announced topline results from a phase 2b study of EGP-437 combination produ…
Patients Are Going Blind Due to 6-Month Waiting Lists for Cataract Surgery
Patients face going blind while waiting for cataract surgery after new figures showed waiting times …
Featured Content
